Edwards Lifesciences EW Europe — Currency translation adjustment
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Edwards Lifesciences in its filing.
Tagged under the XBRL concept us-gaap:GoodwillForeignCurrencyTranslationGainLoss.
The official record: Edwards Lifesciences’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →
Ask your AI about Edwards Lifesciences's europe — currency translation adjustment.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Edwards Lifesciences's europe — currency translation adjustment?
- Edwards Lifesciences (EW) reported europe — currency translation adjustment of $1.75M in Q4 2025.
- How has Edwards Lifesciences's europe — currency translation adjustment changed year-over-year?
- Edwards Lifesciences's europe — currency translation adjustment increased by 333.3% year-over-year, from -$750K to $1.75M.
- What is the long-term trend for Edwards Lifesciences's europe — currency translation adjustment?
- Over 4 years (2021 to 2025), Edwards Lifesciences's europe — currency translation adjustment has grown at a 7.2% compound annual growth rate (CAGR), from -$5.3M to $7M.
- What does europe — currency translation adjustment mean?
- This metric quantifies the impact of fluctuations in foreign exchange rates on the reported value of assets and liabilities within the European segment. It represents the non-cash gains or losses arising from translating local currency financial statements into the company's reporting currency. This is a critical measure for understanding how currency volatility affects the reported performance of international operations.